Future Journal of Pharmaceutical Sciences最新文献

{"title":"Exploratory metaproteomic profiling of the nasal microbiota in a pilot cohort of mothers and infants","authors":"Samah El-Sayed,&nbsp;Samira Zakeer,&nbsp;Samar Solyman,&nbsp;Salah Abdalla,&nbsp;Amro Hanora,&nbsp;Shymaa Enany","doi":"10.1186/s43094-026-00949-0","DOIUrl":"10.1186/s43094-026-00949-0","url":null,"abstract":"<div><h3>Background</h3><p>The nasal passages’ microbial communities are vital to human health and can influence infection processes. In this study, ten nasal samples were obtained, five from mothers and five from their 1- to 2-year-old infants. We studied the proteins of the nasal passage microbiota using the metaproteomic technique. The ten nasal samples collected were initially subjected to in-solution digestion, followed by a series of purification steps to ensure sample quality. Subsequent analysis was performed using LC–MS/MS, and the workflow was finalized with comprehensive data processing and bioinformatic analysis utilizing the UniProt database. The preliminary observations indicated that eight proteins showed differential abundance between the maternal and infant cohorts.</p><h3>Results</h3><p>The eight proteins detected in our exploratory study were found to be of particular importance, as they may be implicated in bacterial pathogenesis, can represent potential drug targets, and may be associated with pathways related to drug resistance. These proteins include amidohydrolase, SLEI domain protein (pf07620 family), histidine kinase (EC 2.7.13.3), RND transporter, GLPGLI family protein, penicillin-binding protein, MFS transporter, and a protein kinase domain-containing protein.</p><h3>Conclusions</h3><p>These observations provide preliminary evidence of how metaproteomics can elucidate the protein interactions within bacterial communities and their interactions with the host, potentially advancing our understanding of infection processes and guiding the development of targeted therapies.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00949-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147363054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-time sensing approaches and antibiofilm strategies for biofilm-associated infections: advances and perspectives on medical devices and clinical contexts","authors":"Darshita Valde,&nbsp;Tukendra Kumar,&nbsp;Satya Eswari Jujjavarapu","doi":"10.1186/s43094-026-00944-5","DOIUrl":"10.1186/s43094-026-00944-5","url":null,"abstract":"<div><h3>Background</h3><p>Biofilms are communities of microorganisms encased in a self-produced extracellular matrix. They can form on living hosts or in the environment, and a diverse range of microbes participate in this process. These include harmful bacteria that can become reservoirs for chronic infections. Biofilms contribute to a broad spectrum of illnesses and the emergence of antibiotic resistance, making infections difficult to treat.</p><p>Biofilms are communities of microorganisms encased in a self-produced extracellular matrix. They can form on living hosts or in the environment, and a diverse range of microbes participate in this process. These include harmful bacteria that can become reservoirs for chronic infections. Biofilms contribute to a broad spectrum of illnesses and the emergence of antibiotic resistance, making infections difficult to treat.</p><h3>Main body of the abstract</h3><p>Biofilm growth is most common on medical devices. Real-time detection and development of antibiofilm drugs are crucial to prevent related infections and ensure human health. This review explores infectious diseases associated with both medical and non-medical devices in humans. Furthermore, advanced detection approaches such as impedimetric, potentiometric, surface acoustic waves, and optical fiber sensors, which tackle the real-time growth of bacterial biofilms, are discussed. Additionally, various strategies to combat bacterial biofilm growth on medical devices are also examined. The future direction of research is also explored, focusing on the disadvantages and limitations of sensors and antibiofilm approaches.</p><h3>Short conclusion</h3><p>In this review, we found that the most powerful and easy-to-use sensing approach is impedimetric biosensor. Additionally, the commonly used antibiofilm approach involves nanoparticle-based drug coating on medical devices. Comprehensively, this review covers all possible directions of sensing approaches and antibiofilm strategies, addressing their challenges and potential solutions.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00944-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147335724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of methods for detecting ciprofloxacin in pharmaceuticals and urine: UV–Vis spectrophotometry versus poly ([Mn(Chr)3]Cl2)/PGE voltammetry","authors":"Abebaw Shitahun Ayicheh,&nbsp;Minaleshewa Atlabachew,&nbsp;Belete Asefa Aragaw,&nbsp;Amare Benor,&nbsp;Bamlaku Abebaw,&nbsp;Atakilt Abebe","doi":"10.1186/s43094-026-00948-1","DOIUrl":"10.1186/s43094-026-00948-1","url":null,"abstract":"<div><h3>Background</h3><p>Ciprofloxacin (Cpro) is a drug belonging to the fluoroquinolones class which can contribute to bacterial resistance due to its improper and overuse, and excretion in urine as unchanged. Therefore, continuous monitoring is required. In this work, voltammetric technique with pencil graphite electrode (PGE) modified by manganese(II)-chrysin complex ([Mn(Chr)₃]Cl₂) has been developed and its performance has been compared with the unmodified PGE working electrode and UV–Vis spectrophotometric method.</p><h3>Results</h3><p>Both the developed and UV–Vis spectrophotometric methods were calibrated using a series of standard solutions of Cpro with increasing concentration in the range of 1–250 µM. After calibrating the two methods, Cpro has been determined in two brands of pharmaceuticals, in urine samples, and in the presence of paracetamol. The values of dynamic range, LoD, and sensitivity for the developed method were 1–250 µM, 0.536 µM, and 0.148, respectively, whereas in UV–Vis spectrophotometric method the dynamic range, LoD, and sensitivity were 1–120 µM, 0.413 µM, and 0.025, respectively.</p><h3>Conclusion</h3><p>Based on slope value, dynamic range, and selectivity the developed method has better performance than UV–Vis spectrophotometric method.</p><h3>Graphical abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00948-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147342459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pracaxi oil (Pentaclethra macroloba)-loaded nanofibers: a promising biomaterial for wound healing","authors":"Eduardo Ricci-Júnior,&nbsp;Luana Santos Monteiro,&nbsp;Ana Carolina Souza de Lima,&nbsp;Anna Lecticia Martinez Martinez Toledo,&nbsp;Marcos Lopes Dias,&nbsp;Tatiana Almeida Pádua,&nbsp;Thadeu Estevam Moreira Maramaldo Costa,&nbsp;Francisco Paiva Machado,&nbsp;Mikaela Amaral Ferreira,&nbsp;Leandro Machado Rocha,&nbsp;Elaine Cruz Rosas,&nbsp;Mariana Sato de Souza Bustamante Monteiro","doi":"10.1186/s43094-026-00938-3","DOIUrl":"10.1186/s43094-026-00938-3","url":null,"abstract":"<div><h3>Background</h3><p>Chronic and complex wounds remain a significant clinical challenge, requiring biomaterials that can provide structural support and bioactive signaling. <i>Pentaclethra macroloba</i> (Pracaxi) oil is recognized for its regenerative properties; its integration into advanced delivery systems, such as electrospun nanofibers, which offer high surface area and mimic extracellular matrix, remains unexplored. This work aimed to develop and characterize poly(lactic acid) (PLA) nanofibers loaded with Pracaxi oil (OP) as an innovative bioactive dressing for wound healing.</p><h3>Methods</h3><p>The chemical profile of OP was determined by gas chromatography-mass spectrometry (GC–MS). PLA/OP nanofibers (1%–20% w/w) were produced via electrospinning process and characterized by scanning electron microscopy (SEM), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), and thermal analysis (DSC/TGA). Biological performance was evaluated using human keratinocyte (HaCaT) viability (MTT assay) and cell migration (scratch assay).</p><h3>Results</h3><p>CG-MS identified 11 fatty acids (98.95%), with oleic acid (50.93%) and behenic acid as the primary bioactive component. OP incorporation influenced fiber diameter and induced the formation of beads, which reduced the mat porosity. The oil acted as a plasticizer, slightly decreasing the glass transition temperature (Tg) and thermal stability, while the amorphous structure of PLA was preserved. Nanofibers containing up to 15% w/w of OP demonstrated excellent biocompatibility, with cell viability exceeding 100%. The 15% w/w of OP formulation was identified as the optimal system, significantly accelerating keratinocyte migration compared to pure PLA and control groups (<i>p</i> &lt; 0.01).</p><h3>Conclusions</h3><p>This study successfully integrated OP into PLA nanofibers for the first time. The resulting membrane combines the structural advantages of nanofibers with the therapeutic benefits of PO. Specifically, the 15% w/w formulation is a promising biomimetic scaffold for wound healing. Future in vivo studies are suggested to confirm these findings.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00938-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147341893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive review on ethnobotany, phytochemistry, traditional and modern uses of chasteberry (Vitex agnus-castus L.)","authors":"Shaza H. Aly,&nbsp;Noha N. Nasr,&nbsp;Riham A. El-Shiekh,&nbsp;Shymaa Hatem,&nbsp;Youssef Hashem Hafez,&nbsp;Amr Bahr,&nbsp;Menna A. Alsadany,&nbsp;Mohamed S. Abd El Hafeez,&nbsp;Abdel-Aziz S. Shatat,&nbsp;Nehal Mohamed Eisa,&nbsp;Rana M. Merghany","doi":"10.1186/s43094-025-00931-2","DOIUrl":"10.1186/s43094-025-00931-2","url":null,"abstract":"<div><p><i>Vitex agnus-castus</i> L. (chaste tree) has a rich history of use in traditional medicine across various cultures for over 2500 years, particularly for gynecological issues. Its applications range from regulating menstrual cycles to alleviating premenstrual syndrome and menopausal symptoms, with endorsements from health authorities such as the German Commission E. This review aims to consolidate existing knowledge on the ethnopharmacological uses, phytochemistry, and pharmacological effects of <i>V. agnus-castus</i>, while also discussing its safety profile and therapeutic potential. The relevant articles were identified by searching PubMed (www.pubmed.com), Scopus (http://www.scopus.com), ISI Web of Science (www.webofknowledge.com), and Google Scholar (www.scholar.google.com) up to November 2024. <i>V. agnus-castus</i> exhibits a wide range of pharmacological properties, including antioxidant, anti-inflammatory, antimicrobial, and cytotoxic effects. Its active compounds, particularly casticin, have been linked to these benefits. Future research should focus on advanced preclinical and clinical studies to better assess its safety and therapeutic efficacy in diverse populations.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-025-00931-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147341096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic potential of rutamarin: preclinical evidence of its biological properties through in silico, in vitro, and in vivo studies","authors":"Shafinah Ahmad Suhaimi,&nbsp;Khairunnisa’ Md Yusof,&nbsp;Norazalina Saad","doi":"10.1186/s43094-026-00945-4","DOIUrl":"10.1186/s43094-026-00945-4","url":null,"abstract":"<div><h3>Background</h3><p>In traditional medicine, natural compounds, such as coumarins, have been recognised as effective therapeutic agents for a variety of ailments. One of the natural furanocoumarins is rutamarin, which can be abundantly found in the Rutaceae family. It has been demonstrated to possess diverse biological properties in preclinical models, underscoring its potential for therapeutic applications in various health problems.</p><h3>Main body</h3><p>This review provides an extensive description and critical evaluation of the biological activities of rutamarin, particularly anticancer, antidepressant, antidiabetic, and antimicrobial effects. To a lesser extent, the antinociceptive, antivenom, and antiviral effects of rutamarin are also included. Scientific preclinical evidence based on in silico, in vitro, and in vivo models is discussed, highlighting its potential as a pharmaceutical agent for therapeutic purposes. As a natural product, the distribution and chemical extraction of rutamarin in plants, as well as its isolation, are also discussed. Moreover, efforts to amplify the yield of rutamarin in in vitro plant cultures and to synthesise rutamarin are briefly described. Since most studies previously utilised in silico analysis to elucidate rutamarin’s mechanism of action, limitations and future directions for clinical trials are also suggested.</p><h3>Conclusion</h3><p>Advancement to clinical trials is a crucial step towards utilising rutamarin as a therapeutic agent for various diseases and health complications, including cancers, diabetes, and microbial infections. However, current findings that largely rely on in silico and in vitro models need further preclinical validation of the biological properties, especially in vivo models, which are essential prior to advancement to clinical setting.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00945-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147340505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models","authors":"Sara Muhammad El-Hanboshy,&nbsp;Ihab T. Abdel-Raheem,&nbsp;Maged Wasfy Helmy","doi":"10.1186/s43094-026-00937-4","DOIUrl":"10.1186/s43094-026-00937-4","url":null,"abstract":"<div><h3>Background</h3><p>Lung cancer is the prime cause of cancer-related death worldwide. It is an aggressive malignant tumor characterized by significant dysregulation of various oncogenic and immunosurveillance pathways. STAT3 is considered to be a point of convergence of such pathways, so it is an attractive therapeutic target for lung cancer. Hence, the current study aimed to investigate the anticancer activity of baricitinib and/or rosuvastatin as repurposed drugs known to inhibit STAT3.</p><h3>Methods and results</h3><p>In vitro experiments were conducted using two NSCLC cell lines (A549 and H460), and the MTT test was used to assess the cytotoxic activity of both drugs and their combination. Moreover, selected oncogenic proteins were quantified. In addition, in vivo experiments were also performed using a urethane-induced lung cancer mice model. Both drugs showed excellent anticancer activities along with outstanding synergism when combined. Baricitinib and/or rosuvastatin inhibited cancer cell proliferation, migration, and angiogenesis in addition to inducing apoptosis. Furthermore, they exhibited immunoediting effects against cancer via significant suppression of PD-L1 and CTLA-4 inhibitory immune checkpoints.</p><h3>Conclusion</h3><p>The current study highlights the potential therapeutic benefits of baricitinib as an anticancer agent, for the first time, and/or rosuvastatin as repurposed drugs that can be used in lung cancer treatment.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div><p>Created in BioRender.\u0000El-hanboshy, S. (2025) https://BioRender.com/l95u186.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00937-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147339806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmaceutical nanotechnology research in Egypt: prospects in treatment of liver diseases, patenting, and regulatory implications","authors":"Maha Nasr,&nbsp;Ahmed M. Kabel,&nbsp;Fatma S. Abdel-Salam,&nbsp;Nadia M. Hamdy","doi":"10.1186/s43094-026-00942-7","DOIUrl":"10.1186/s43094-026-00942-7","url":null,"abstract":"<div><h3>Background</h3><p>The application of nanotechnology in the biomedical field has greatly expanded in the last decade, as delineated by the large number of publications by several researchers. Particularly for liver diseases which are prevalent in Egypt, published research has delineated that nanotechnology-based products were able to enhance the therapeutic efficacy and safety of drugs, by modulating their distribution and pharmacokinetic properties, protecting them from degradation, reducing their renal clearance and elimination, enhancing liver specific uptake and targeting, and overcoming mechanisms of drug resistance. However, surveying the granted patents in this regard displayed the limited number of patents, concurring with limited availability of nanotechnology-based products in the market.</p><h3>Areas covered</h3><p>This review article firstly details the research conducted in Egypt for treatment of prevalent liver diseases using nanotechnology-based products, then details the granted patents in Egypt and internationally in this regard, followed by an overview on the existing safety and regulatory implications, and recommendations for their improvement, in order to increase the number of commercially available products in the market.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00942-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147339539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the clinical outcomes of prolonged versus intermittent infusion of meropenem in critically ill pediatric patients: a randomized double-blind single-center study","authors":"Rania Saad Mahmoud,&nbsp;Maher Mukhtar Ahmed,&nbsp;Sahar Badr Hassan,&nbsp;Mohamed Mahmoud Mohamed Abdel-Latif","doi":"10.1186/s43094-026-00935-6","DOIUrl":"10.1186/s43094-026-00935-6","url":null,"abstract":"<div><h3>Background</h3><p>Optimal antibiotic dosing strategies, such as prolonged infusion (PI), are hypothesized to improve clinical outcomes in critically ill patients by maximizing time above the minimum inhibitory concentration. This prospective study aimed to evaluate whether PI of meropenem enhances clinical outcomes and reduces mortality compared to standard intermittent infusion (II) in pediatric patients diagnosed with culture-negative sepsis in the pediatric intensive care unit (PICU).</p><h3>Methods</h3><p>A prospective, double-blind, randomized, clinical study was conducted in PICU between May 2019 and November 2019 aimed to evaluate whether PI of meropenem enhances clinical outcomes and reduces mortality in pediatric patients diagnosed with culture-negative sepsis. Eligible patients with culture-negative sepsis were assigned to receive meropenem as either a 3-h PI or a 30-min II administered at a dose of 60 mg/kg/day every 8 h. The primary endpoint was clinical improvement that was defined as a reduction in the pediatric Sequential Organ Failure Assessment (pSOFA) score on the 7th day of meropenem therapy. Secondary outcomes included PICU mortality, C-reactive protein (CRP) level, and length of stay in the PICU.</p><h3>Results</h3><p>Baseline characteristics were comparable between the two groups (age, gender, CRP, and pre-treatment pSOFA score). By the 7th day of meropenem therapy, the PI group showed greater clinical improvement, as evidenced by a significantly lower pSOFA score compared to the II group [(median pSOFA score: 1; IQR (4)] versus [(median pSOFA score: 4; IQR: (9.75)] in II group (<i>p</i> = 0.008). The 14-day mortality rate in the PICU was lower among patients receiving PI compared to those treated with II (24.2% vs 57.1%, <i>p</i> &lt; 0.001). CRP showed a greater reduction in the PI compared to the II group (35% vs 105.25%, <i>p</i> = 0.028). Both groups did not differ significantly concerning PICU length of stay (<i>p</i> = 0.104). The ∆pSOFA score showed excellent predictive accuracy (AUC = 0.946) for early treatment response in critically ill pediatric patients, with a cutoff of − 2.5 yielding high sensitivity and specificity. Kaplan–Meier analysis demonstrated a statistically significant difference in survival between the two groups (log-rank <i>p</i> = 0.026), highlighting the impact of treatment strategy on patient outcomes.</p><h3>Conclusion</h3><p>PI of meropenem was associated with enhanced clinical improvement and reduced mortality rates in pediatric patients with culture-negative sepsis.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00935-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147339241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Belotecan in ovarian cancer anti-inflammatory potential and mechanistic insight to nano-formulations","authors":"Ajay Kumar,&nbsp;Gesu Singla,&nbsp; Amita,&nbsp;Brahmjot Singh,&nbsp;Pooja Sharma,&nbsp;Sandeep Kaur,&nbsp;Poonam Chaturvedi,&nbsp;Bunty Sharma,&nbsp;Shafiul Haque,&nbsp;Hardeep Singh Tuli","doi":"10.1186/s43094-026-00940-9","DOIUrl":"10.1186/s43094-026-00940-9","url":null,"abstract":"<div><h3>Background</h3><p>Ovarian cancer is a major gynecologic malignancy with high morbidity and mortality rates. Current treatment options have limited long-term effectiveness due to tumor resistance and significant side effects.</p><h3>Main body</h3><p>This article explores the potential of belotecan, a derivative of camptothecin, as a promising therapeutic agent for ovarian cancer. Belotecan’s ability to inhibit topoisomerase I, induce DNA damage, and modulate inflammation positions it as a strong candidate for enhancing ovarian cancer treatment. However, challenges such as poor bioavailability, rapid systemic clearance, and dose-limiting toxicity remain. To overcome these issues, nano-formulation strategies are proposed to improve pharmacokinetics, solubility, and tumor-specific targeting. These strategies may enhance belotecan's stability, increase its therapeutic efficacy, and minimize off-target effects.</p><h3>Conclusion</h3><p>This review provides a detailed examination of belotecan’s molecular mechanisms, its anti-inflammatory and anti-cancer properties, and the advances in nano-formulation technologies. The integration of these strategies could lead to more effective treatments and improved outcomes for ovarian cancer patients.</p><h3>Graphical abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00940-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147339033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}